牛牛AI助手已提取核心信息
On February 2, 2024, Cardio Diagnostics Holdings, Inc. completed a private placement transaction with seven accredited investors, issuing 561,793 units for gross proceeds of $1,000,000. Each unit consists of one share of common stock and a six-year warrant to purchase additional shares at $1.78 each. The company plans to register these shares and warrants for resale within 180 days and has granted the investors rights to participate in future financings until February 2, 2025, with certain exceptions. The placement agent, Altitude Capital Group, LLC, received a 10% commission and 20% warrant coverage on the transaction. The company's Chairman of the Board, Dr. Warren Hosseinion, who holds a 10% interest in Altitude Capital, recused himself from board decisions regarding the placement. The funds raised are intended for working capital and general corporate purposes. The securities were issued in reliance on exemptions from registration requirements under the Securities Act of 1933.
On February 2, 2024, Cardio Diagnostics Holdings, Inc. completed a private placement transaction with seven accredited investors, issuing 561,793 units for gross proceeds of $1,000,000. Each unit consists of one share of common stock and a six-year warrant to purchase additional shares at $1.78 each. The company plans to register these shares and warrants for resale within 180 days and has granted the investors rights to participate in future financings until February 2, 2025, with certain exceptions. The placement agent, Altitude Capital Group, LLC, received a 10% commission and 20% warrant coverage on the transaction. The company's Chairman of the Board, Dr. Warren Hosseinion, who holds a 10% interest in Altitude Capital, recused himself from board decisions regarding the placement. The funds raised are intended for working capital and general corporate purposes. The securities were issued in reliance on exemptions from registration requirements under the Securities Act of 1933.
2024年2月2日，Cardio Diagnostics Holdings, Inc.完成了与七名合格投资者的私募交易，发行了561,793套，总收益为100万美元。每个单位由一股普通股和一份六年期认股权证组成，用于以每股1.78美元的价格购买额外股票。该公司计划在180天内注册这些股票和认股权证进行转售，并已授予投资者在2025年2月2日之前参与未来融资的权利，但有某些例外情况。配售代理机构Altitude Capital Group, LLC从该交易中获得了10％的佣金和20％的认股权证。该公司董事会主席沃伦·霍塞尼恩博士持有Altitude Capital10％的权益，他回避了董事会关于此次配售的决定。筹集的资金用于营运资金和一般公司用途。这些证券是根据1933年《证券法》的注册要求豁免发行的。
2024年2月2日，Cardio Diagnostics Holdings, Inc.完成了与七名合格投资者的私募交易，发行了561,793套，总收益为100万美元。每个单位由一股普通股和一份六年期认股权证组成，用于以每股1.78美元的价格购买额外股票。该公司计划在180天内注册这些股票和认股权证进行转售，并已授予投资者在2025年2月2日之前参与未来融资的权利，但有某些例外情况。配售代理机构Altitude Capital Group, LLC从该交易中获得了10％的佣金和20％的认股权证。该公司董事会主席沃伦·霍塞尼恩博士持有Altitude Capital10％的权益，他回避了董事会关于此次配售的决定。筹集的资金用于营运资金和一般公司用途。这些证券是根据1933年《证券法》的注册要求豁免发行的。
有用
没用
